Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities-Reference-Cited by-同舟云学术

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Published:2020-07-22 Issue:8 Volume:9 Page:419-427
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Al‐Huniti Nidal¹,Feng Yan²,Yu Jingyu (Jerry)³,Lu Zheng⁴,Nagase Mario⁵,Zhou Diansong⁵,Sheng Jennifer²

Affiliation:

1. Quantitative Pharmacology Regeneron Pharmaceuticals New York New York USA

2. Clinical Pharmacology and Pharmacometrics Bristol‐Myers Squibb Lawrenceville New Jersey USA

3. Division of Pharmacometrics US Food and Drug Administration Silver Spring Maryland USA

4. Clinical Pharmacology and Pharmacometrics Astellas Illinois USA

5. Department of Clinical Pharmacology and Safety Science BioPharmaceuticals R&D AstraZeneca Boston Massachusetts USA

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12542

Reference57 articles.

1. Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma

2. The mathematics of cancer: integrating quantitative models

3. Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development

4. A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology

5. Sheng J.et al.Association of Fc‐Gamma receptor polymorphism (CD16a) and clinical benefits of elotuzumab in combination with lenalidomide and dexamethasone: tumor growth dynamics best overall response and progress‐free survival. ASCPT March 2017 (Washington DC 2017).

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bridging the gap between two‐stage and joint models: The case of tumor growth inhibition and overall survival models;Statistics in Medicine;2024-06-03

2. Realizing the Promise of Project Optimus: Challenges and Emerging Opportunities for Dose Optimization in Oncology Drug Development;CPT: Pharmacometrics & Systems Pharmacology;2023-11-15

3. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment;PLOS Computational Biology;2023-10-04

4. Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework;Clinical Pharmacology & Therapeutics;2023-06-02

5. A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development;Journal of Pharmacokinetics and Pharmacodynamics;2023-03-04